期刊文献+

补中益气五苓汤联合卡维地洛治疗老年慢性心力衰竭疗效观察 被引量:2

Efficacy of Buzhong Yiqi Wuling Decoction combined with carvedilol in the treatment of chronic heart failure in the elderly
下载PDF
导出
摘要 目的观察补中益气五苓汤联合卡维地洛治疗老年慢性心力衰竭的临床疗效。方法选择2018年4月至2019年4月西安市中医医院收治的100例老年慢性心力衰竭患者作为研究对象,采用随机数表法分为观察组和对照组各50例。对照组采用卡维地洛治疗,观察组在此基础上联合补中益气五苓汤治疗。治疗10周后比较两组患者的治疗效果、治疗前及治疗10周后的中医证候积分、血浆N端脑钠肽(NT-proBNP)水平、左射血分数(LVEF)、左室舒张末期内径(LVEDD)、右心室收缩末期(LVESD)变化和不良反应。结果观察组患者的治疗总有效率为94.0%,明显高于对照组的78.0%,差异有统计学意义(P<0.05);治疗后,两组患者的中医证候积分、NT-proBNP水平明显降低,且观察组[(5.10±0.98)分、(518.13±18.41) pg/mL]明显低于对照组[(8.29±1.52)分、(658.39±20.14) pg/mL],差异均有统计学意义(P<0.05);治疗后,两组患者的LVEDD、LVESD明显降低,且观察组[(45.19±3.97) mm、(37.13±3.68) mm]明显低于对照组[(50.13±4.27) mm、(43.52±4.27) mm],而LVEF明显升高,观察组为(49.10±4.18)%,明显高于对照组的(42.52±3.69)%,差异均有统计学意义(P<0.05);观察组和对照组患者治疗期间的总不良反应发生率比较差异无统计学意义(P>0.05)。结论补中益气五苓汤联合卡维地洛治疗老年慢性心力衰竭疗效良好,其可有效改善患者的临床症状和心功能,值得临床推广应用。 Objective To observe the clinical efficacy of Buzhong Yiqi Wuling Decoction combined with carvedilol in the treatment of elderly chronic heart failure.Methods A total of 100 elderly patients with chronic heart failure admitted to Xi'an Hospital of Traditional Chinese Medicine from April 2018 to April 2019 were selected and divided into the observation group and control group according to random number table method,with 50 patients in each group.The control group was treated with carvedilol,and the observation group was treated with Buzhong Yiqi Wuling Decoction on this basis.After 10 weeks of treatment,the treatment effects of the two groups,including TCM syndrome scores before and after 10 weeks of treatment,plasma N-terminal brain natriuretic peptide(NT-proBNP)levels,left ejection fraction(LVEF),left ventricular end diastole internal diameter(LVEDD),right ventricular end systole(LVESD)changes and adverse reactions were compared.Results The total effective rate of treatment in the observation group was 94.0%,which was significantly higher than 78.0%in the control group(P<0.05).After treatment,TCM syndrome score and NT-proBNP of both groups decreased,and those in the observation group were(5.10±0.98)points,(518.13±18.41)pg/mL,significantly lower than(8.29±1.52)points,(658.39±20.14)pg/mL in the control group(P<0.05);LVEDD and LVESD of both groups decreased,and those in the observation group were(45.19±3.97)mm,(37.13±3.68)mm,significantly lower than(50.13±4.27)mm,(43.52±4.27)mm in the control group(P<0.05);LVEF increased,and that in the observation group was(49.10±4.18)%,significantly higher than(42.52±3.69)%in the control group(P<0.05);there was no significant difference in the incidence of total adverse reactions between the observation group and the control group(P>0.05).Conclusion Buzhong Yiqi Wuling Decoction combined with carvedilol has a good effect in the treatment of chronic heart failure in the elderly.It can effectively improve the clinical symptoms and heart function of patients and is worthy of clinical application.
作者 郭王斌 牛静虎 曹建茹 GUO Wang-bin;NIU Jing-hu;CAO Jian-ru(Department of Geriatrics,Xi'an Hospital of Traditional Chinese Medicine,Xi'an 710021,Shaanxi,CHINA;Department of Rheumatology and Immunology,Xi'an Hospital of Traditional Chinese Medicine,Xi'an 710021,Shaanxi,CHINA;Traditional Chinese Medicine Department,Xi'an Lianhu District,Cao Qinghua Traditional Chinese Medicine Clinic,Xi'an 710003,Shaanxi,CHINA)
出处 《海南医学》 CAS 2020年第23期3029-3032,共4页 Hainan Medical Journal
关键词 慢性心力衰竭 老年 卡维地洛 补中益气五苓汤 心功能 不良反应 Chronic heart failure Elderly Carvedilol Buzhong Yiqi Wuling Decoction Heart function Adverse reactions
  • 相关文献

参考文献9

二级参考文献123

  • 1陈发秀,胡坚,邱元芝,尹绢,曹平良,张志勇.髓过氧化物酶在老年慢性心力衰竭患者中的临床意义[J].实用老年医学,2013,27(1):50-52. 被引量:5
  • 2王方正,张澍,黄德嘉,华伟,孙宝贵,沈法荣,吴书林,王建安,方全,吴立群,王景峰,王冬梅,郭涛,陈新,中华医学会心电生理和起搏分会心脏再同步治疗专家工作组.心脏再同步治疗慢性心力衰竭的建议[J].中华心律失常学杂志,2006,10(2):90-102. 被引量:90
  • 3廖业敏,李宗开,程贞华,何君.卡维地洛对慢性心力衰竭患者心肌重构和炎性细胞因子的影响[J].中国心血管病研究,2007,5(7):530-532. 被引量:5
  • 4Colucci WS. Molecular and cellular mechanisms of myocardial failure. Am J Cardiol, 1997, 80(11A) : 15L-25L
  • 5Braunwald E,Bristow MR Congestive heart failure: fifty years of progress. Circulation, 2000, 102(20 Suppl 4) : Ⅳ14-23.
  • 6Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) : developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation, 2005, 112 (12) :e154-235.
  • 7Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary ( update 2005 ):The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J, 2005, 26(11): 1115-1140.
  • 8Arnold JM, Liu P, Demers C, et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006 : diagnosis and management. Can J Cardiol, 2006, 22 (1): 23-45.
  • 9Heart Failure Society of America. HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail, 2006, 12 ( 1 ) : e1-2.
  • 10Enright PL, Sherrill DL Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med, 1998, 158(5 pt 1) :1384-1387.

共引文献3798

同被引文献34

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部